Dr. Reddy's Laboratories Limited vs Perrigo Company plc: A Gross Profit Performance Breakdown

Pharma Giants' Profit Battle: Dr. Reddy's vs. Perrigo

__timestampDr. Reddy's Laboratories LimitedPerrigo Company plc
Wednesday, January 1, 2014758010000001447700000
Thursday, January 1, 2015854030000001712400000
Friday, January 1, 2016922810000002051800000
Sunday, January 1, 2017783560000001979500000
Monday, January 1, 2018763040000001831500000
Tuesday, January 1, 2019834300000001773300000
Wednesday, January 1, 2020940090000001815200000
Friday, January 1, 20211030770000001416200000
Saturday, January 1, 20221138400000001455400000
Sunday, January 1, 20232029720000001680400000
Monday, January 1, 2024163607000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Pharmaceutical Giants: Gross Profit Analysis

In the competitive world of pharmaceuticals, Dr. Reddy's Laboratories Limited and Perrigo Company plc have showcased contrasting financial trajectories over the past decade. From 2014 to 2023, Dr. Reddy's Laboratories consistently outperformed Perrigo in terms of gross profit. Notably, Dr. Reddy's saw a staggering 167% increase in gross profit, peaking in 2023. In contrast, Perrigo's performance remained relatively stable, with minor fluctuations, peaking in 2016.

Dr. Reddy's Laboratories' strategic expansions and innovations have likely contributed to its robust growth, while Perrigo's steady figures suggest a focus on maintaining its existing market share. The data for 2024 is incomplete, but the trends suggest Dr. Reddy's will continue its upward trajectory. This analysis highlights the dynamic nature of the pharmaceutical industry and the importance of strategic planning in achieving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025